keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/28915592/targeted-alpha-therapy-using-a-novel-cd70-targeted-thorium-227-conjugate-in-in-vitro-and-in-vivo-models-of-renal-cell-carcinoma
#1
Urs B Hagemann, Dessislava Mihaylova, Steinar R Uran, Joergen Borrebaek, Derek Grant, Roger M Bjerke, Jenny Karlsson, Alan S Cuthbertson
The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell carcinoma. We describe herein the characterization and efficacy of a novel CD70 targeted thorium-227 conjugate (CD70-TTC) comprising the combination of the three components, a CD70 targeting antibody, a chelator moiety and the short-range, high-energy alpha-emitting radionuclide thorium-227 ((227)Th). In vitro analysis demonstrated that the CD70-TTC retained binding affinity to its target and displayed potent and specific cytotoxicity compared to an isotype control-TTC...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28910148/bulk-scale-formulation-of-therapeutic-doses-of-clinical-grade-ready-to-use-177-lu-dota-tate-the-intricate-radiochemistry-aspects
#2
Anupam Mathur, Vrinda Prashant, Navin Sakhare, Sudipta Chakraborty, K V Vimalnath, Repaka Krishna Mohan, Chanda Arjun, Barkha Karkhanis, Ravi Seshan, Sandip Basu, Aruna Korde, Sharmila Banerjee, Ashutosh Dash, Satbir Singh Sachdev
INTRODUCTION: (177)Lu-DOTA-TATE is a clinically useful and promising therapeutic radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors (NETs) overexpressing somatostatin receptors. Currently, the radiopharmaceutical is prepared in-house at nuclear medicine centers, thereby restricting its use to limited centers only. In this article, the authors describe systematic studies toward bulk scale formulation of "ready-to-use" (177)Lu-DOTA-TATE using medium specific activity (177)Lu (740-1110 GBq/mg) at a centralized radiopharmacy facility...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28903443/radioligand-therapy-of-metastatic-prostate-cancer-using-177-lu-psma-617-after-radiation-exposure-to-223-ra-dichloride
#3
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Florian C Gaertner, Xiao Wei, Stefan Hauser, Markus Essler
Radioligand therapy with (177)Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with (223)Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of (177)Lu-PSMA-617 after exposure to more cycles of (223)Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with (223)Ra...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902781/efficacy-of-peptide-receptor-radionuclide-therapy-in-a-united-states-based-cohort-of-metastatic-neuroendocrine-tumor-patients-single-institution-retrospective-analysis
#4
Bryson W Katona, Giorgio A Roccaro, Michael C Soulen, Yu-Xiao Yang, Bonita J Bennett, Brian P Riff, Rebecca A Glynn, Damian Wild, Guillaume P Nicolas, Daniel A Pryma, Ursina R Teitelbaum, David C Metz
OBJECTIVES: The aim of this study was to analyze in a retrospective cohort study the outcomes of a United States-based group of metastatic neuroendocrine tumor (NET) patients who underwent peptide receptor radionuclide therapy (PRRT). METHODS: Twenty-eight patients from a single US NET Center were treated with PRRT. Toxicities were assessed using Common Terminology Criteria for Adverse Events version 4.03. Progression was determined by the Response Evaluation Criteria in Solid Tumors version 1...
October 2017: Pancreas
https://www.readbyqxmd.com/read/28902732/multimodality-radionuclide-imaging-in-a-patient-with-hereditary-paraganglioma-pheochromocytoma-syndrome
#5
So Y Yim, Valeria M Moncayo, Francisco J Pasquel, Raghuveer K Halkar
Hereditary paraganglioma (PGL)-pheochromocytoma (PCC) syndrome is a genetic disorder caused by a mutation of the tumor suppressor gene SDHD that results in a predisposition for head and neck PGLs and PCCs. We present a case of a 33-year-old woman where F-FDG PET/CT showed areas of increased uptake in both the adrenal and cervical regions, consistent with PCCs and PGLs, respectively. Further imaging revealed that PCCs were I-MIBG avid, whereas the PGLs were In-octreotide avid. This demonstrates the varying sensitivities of different imaging modalities in regard to neuroendocrine tumors and the potential for treatment using multiple targeted therapies...
September 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28901480/radioiodine-labeled-anti-epidermal-growth-factor-receptor-binding-bovine-serum-albumin-polycaprolactone-for-targeting-imaging-of-glioblastoma
#6
Chengxia Li, Jian Tan, Jin Chang, Wei Li, Zhongyun Liu, Ning Li, Yanhui Ji
The aim of this study was to look for a new medicine in diagnosing and treating of glioblastoma. Radioiodine-labeled anti-epidermal growth factor receptor (EGFR) binding nanoparticles were constructed. In vitro cell-binding assays were confirmed by confocal microscopy and flow cytometry. Cell cytotoxicity assays were evaluated by MTT assay; radionuclide uptake assays were performed by γ-counter. Radioiodine-imaging studies were conducted using a xenograft nude mouse model in vivo. The results showed that EGFR significantly enhanced the uptake and accumulation of BSA-PCL in the experimental model of xenografts in nude mice, suggesting improved specific nanoparticle-based delivery...
September 4, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28898798/free-disease-long-term-survival-in-primary-thoracic-spine-leiomyosarcoma-after-total-en-bloc-spondylectomy-a-case-report
#7
José Ramirez-Villaescusa, Adriana Canosa-Fernández, Antonio Martin-Benlloch, David Ruiz-Picazo, Jesús López-Torres Hidalgo
INTRODUCTION: To describe an unusual primary vertebral leiomyosarcoma in thoracic spine. PRESENTATION OF CASE: An isolated lesion of the T11 vertebra in a 62-year-old woman with no neurologic deficit is reported. Imaging findings indicated a nonspecific high-grade malignant lesion. TC-guided biopsy failed thus open incisional biopsy was needed. A diagnosis of low-intermediate mesenchymal sarcoma was made. A total en bloc spondylectomy of T11 was performed with three-column reconstruction...
September 1, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28894897/peptide-receptor-radionuclide-therapy-prrt-in-european-neuroendocrine-tumour-society-enets-grade-3-g3-neuroendocrine-neoplasia-nen-a-single-institution-retrospective-analysis
#8
Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks
PURPOSE: Grade 3 NENs are aggressive tumours with poor prognosis. PRRT+/- radiosensitising chemotherapy is a potential treatment for disease with high somatostatin receptor (SSTR) expression without spatially discordant FDG-avid disease. We retrospectively evaluated the efficacy of PRRT in G3 NEN. METHODS: Kaplan-Meier estimation was used to determine progression-free survival (PFS) and overall survival (OS) defined from start of PRRT. Subgroup analysis was performed for patients with Ki-67 ≤ 55% and >55%...
September 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28878845/influence-of-androgen-deprivation-therapy-on-the-uptake-of-psma-targeted-agents-emerging-opportunities-and-challenges
#9
REVIEW
Martin K Bakht, So Won Oh, Hyewon Youn, Gi Jeong Cheon, Cheol Kwak, Keon Wook Kang
Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs...
September 2017: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28875837/nanoparticles-for-spect-and-pet-imaging-towards-personalized-medicine-and-theranostics
#10
Andras Polyak, Tobias L Ross
PET and SPECT imaging methods can be of excellent assistance for the development of new nanoparticle drug delivery systems, and at the same time, these investigations also offer the opportunity to produce exceptional new diagnostic and therapeutic radiopharmaceuticals, as well. With a multifunctional, nano-scaled drug delivery system, the diagnostic (imaging) methods and the therapy (delivering drugs or beta-emitter radionuclides) can be carried out using the same biological and pharmacological mechanisms. By combining therapy and diagnostics in one method or in one specifically targeted nanoparticle system, we can product theranostic pharmaceuticals, and its applications are important elements of personalized medicine...
August 29, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28872546/68ga-dota-tate-pet-ct-for-molecular-imaging-of-somatostatin-receptor-expression-in-metastasizing-epithelioid-hemangioendothelioma-comparison-with-18f-fdg
#11
Thorsten Derlin, Katja Hueper, Bisharah Soudah
Epithelioid hemangioendothelioma (EHE) is a rare tumor originating from vascular endothelial or pre-endothelial cells. It has the potential to metastasize. We present the case of a 51-year-old woman with metastasizing EHE who underwent both F-FDG and Ga-DOTA-TATE PET/CT for staging of disease and for evaluation of targeted radionuclide therapy potential. On Ga-DOTA-TATE PET scans, intense tracer accumulation was observed in metastases. Besides the increased glucose metabolism in EHE, this case highlights the potential of Ga-DOTA-TATE PET/CT for restaging of EHE and the option of targeted radionuclide therapy in this entity...
September 1, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28868578/management-of-pulmonary-neuroendocrine-tumors
#12
REVIEW
Robert A Ramirez, Aman Chauhan, Juan Gimenez, Katharine E H Thomas, Ioni Kokodis, Brianne A Voros
Neuroendocrine tumors (NETs) of the lung are divided into 4 major types: small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC) or typical carcinoid (TC). Each classification has distinctly different treatment paradigms, making an accurate initial diagnosis essential. The inconsistent clinical presentation of this disease, however, makes this difficult. The objective of this manuscript is to detail the diagnosis and management of the well differentiated pulmonary carcinoid (PC) tumors...
September 4, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28865367/the-role-of-radionuclide-probes-for-monitoring-anti-tumor-drugs-efficacy-a-brief-review
#13
REVIEW
Renata Salgado Fernandes, Carolina de Aguiar Ferreira, Daniel Cristian Ferreira Soares, Anna Margherita Maffione, Danyelle M Townsend, Domenico Rubello, André Luís Branco de Barros
Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy...
August 30, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28864881/improving-quality-of-life-in-patients-with-pancreatic-neuroendocrine-tumor-following-peptide-receptor-radionuclide-therapy-assessed-by-eortc-qlq-c30
#14
Milka Marinova, Martin Mücke, Lukas Mahlberg, Markus Essler, Henning Cuhls, Lukas Radbruch, Rupert Conrad, Hojjat Ahmadzadehfar
INTRODUCTION: Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT. METHODS: Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8)...
September 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28864631/radionuclide-tumor-targeting-using-adapt-scaffold-proteins-aspects-of-label-positioning-and-residualizing-properties-of-the-label
#15
Sarah Lindbo, Javad Garousi, Bogdan Mitran, Mohamed Altai, Jos Buijs, Anna Orlova, Sophia Hober, Vladimir Tolmachev
Visualization of cancer-associated alterations of molecular phenotype using radionuclide imaging is a non-invasive approach to stratify patients for targeted therapies. The engineered scaffold protein ABD-.derived affinity protein (ADAPT) is a promising tracer for radionuclide molecular imaging due to its small size (6.5 kDa), that provides precondition for efficient tumor penetration and rapid clearance. Previous studies demonstrated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 labeled with radiometals at the N-terminus provides imaging of HER2 expression in xenografts a few hours after injection...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864620/individualized-dosimetry-for-theranostics-necessary-nice-to-have-or-counterproductive
#16
Uta Eberlein, Marta Cremonesi, Michael Lassmann
In 2005, the term theragnostics (theranostics) was introduced for describing the use of imaging for therapy planning in radiation oncology. In nuclear medicine, this expression describes the use of tracers for predicting the absorbed doses in molecular radiotherapy and, thus, the safety and efficacy of a treatment. At present, the most successful groups of isotopes for this purpose are (123)I/(124)I/(131)I, (68)Ga/(177)Lu, and (111)In/(86)Y/(90)Y. The purpose of this review is to summarize available data on the dosimetry and dose-response relationships of several theranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864614/somatostatin-receptor-antagonists-for-imaging-and-therapy
#17
Melpomeni Fani, Guillaume P Nicolas, Damian Wild
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE). PET/CT with (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864613/somatostatin-receptor-2-targeting-compounds
#18
Daan A Smit Duijzentkunst, Dik J Kwekkeboom, Lisa Bodei
The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone in the development of theranostic compounds. Whole-body scintigraphy with (111)In-pentetreotide has revolutionized the diagnosis and staging of NETs and the evaluation of treatment outcomes. At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%. Peptide receptor radionuclide therapy (PRRT) has become a well-accepted treatment for patients with well-differentiated inoperable or metastatic NETs and disease progression after first-line treatment...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864612/clinical-history-of-the-theranostic-radionuclide-approach-to-neuroendocrine-tumors-and-other-types-of-cancer-historical-review-based-on-an-interview-of-eric-p-krenning-by-rachel-levine
#19
Rachel Levine, Eric P Krenning
In nuclear medicine, the term theranostics describes the combination of therapy and diagnostic imaging. In practice, this concept dates back more than 50 years; however, among the most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors. The development of these modalities through the radiolabeling of somatostatin analogs with various radionuclides has led to a revolution in patient management and established a foundation for expansion of the theranostic principle into other oncology indications...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864611/norepinephrine-transporter-as-a-target-for-imaging-and-therapy
#20
Neeta Pandit-Taskar, Shakeel Modak
The norepinephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adrenal chromaffin cells. In neuroendocrine tumors, NET can be targeted for imaging as well as therapy. One of the most widely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of norepinephrine. (123)I/(131)I-MIBG theranostics have been applied in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, paraganglioma, and pheochromocytoma...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"